Pfizer proudly flaunts its “World’s Most Ethical Companies” award, but this honor is a pay-to-play scheme, not a genuine ...
Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...
Johnson & Johnson signed a multibillion-dollar contract with ChemImage in 2019. The two companies will face off in court next ...
The University of Michigan's index of consumer sentiment tumbled 10.5% on a monthly basis in March and plunged 27.1% over the ...
2d
Zacks Investment Research on MSNAlnylam Rallies 62% in a Year: Can the Stock Maintain This Momentum?Alnylam Pharmaceuticals ALNY focuses on developing novel therapeutics based on RNAi technology. The company’s pipeline of ...
While modern society’s relationship with mental health as evolved in recent decades, pharmaceutical innovation has yet to keep pace, mostly due ...
EAST WHITELAND — Endo, a pharmaceutical company that has its global headquarters in Chester County, is being acquired by ...
Trump threatened to enact 200% tariffs on all alcoholic products coming from the European Union in retaliation for the bloc’s ...
Despite early success, Verona's lack of specific 2025 guidance and competition from Dupixent and other drugs raise concerns.
Dublin-headquartered Mallinckrodt is taking over smaller rival Endo and planning to list the combined firm on the New York Stock Exchange, the two drugmakers said Thursday.
Ireland’s Mallinckrodt will buy U.S. drugmaker Endo in a cash-and-stock deal valued at $6.7 billion. The companies said ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results